AngioChem is a clinical-stage biotech that uses its EPiC platform to develop drugs that can cross the blood-brain barrier, which is a major challenge for treating brain diseases. The company's Engineered Peptide Compounds have the potential to treat a wide range of central nervous system diseases, including brain cancer, brain metastases, lysosomal storage diseases, and pain. By using a receptor-based approach, AngioChem's drugs can effectively address medical needs that were previously difficult to treat due to the blood-brain barrier.